Finance

Lists
IKT:NASDAQ
Inhibikase Therapeutics Inc
USD 1,52
-0,65%
(-0,0100) 1D
13 Nov., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IKT...
Open
USD 1,56
High
USD 1,58
Low
USD 1,48
Mkt. cap
213,21 m
Avg. vol.
640,18 k
Volume
0,00
52-wk high
USD 2,61
52-wk low
USD 1,40
EPS
-USD 0,44
Beta
0,94
Shares outstanding
140,27 m
No. of employees
35
Open
USD 1,56
High
USD 1,58
Low
USD 1,48
Mkt. cap
213,21 m
Avg. vol.
640,18 k
Volume
0,00
52-wk high
USD 2,61
52-wk low
USD 1,40
EPS
-USD 0,44
Beta
0,94
Shares outstanding
140,27 m
No. of employees
35
News stories
From web sources and news partners
About Inhibikase Therapeutics Inc
CEO-
Employees35
Founded2008
HeadquartersWilmington, Delaware, Verenigde State van Amerika
SectorHealth Care
Industry-
Analyst ratings
Based on 5 analysts giving stock ratings to IKT in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IKT in the last 3 months.
Highest
Current USD 1,52
USD 8,00 (+426,32%)
Average
USD 5,50 (+261,84%)
Lowest
USD 1,50 (-1,32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
USD 8,00
+426,3%
11/13/2026
Jason McCarthy
Maxim Group
Buy
Maintained
USD 8,00
+426,3%
11/11/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
USD 5,00
+228,9%
11/11/2026
Andreas Argyrides
Chardan Capital
Hold
Initiated
USD 1,50
-1,3%
10/13/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
USD 5,00
+228,9%
09/15/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
USD 6,00
+294,7%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
USD 4,00
+163,2%
05/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
USD 4,00
+163,2%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
-
-
-
-
Cost of goods sold
-21,63 m
-
-
-
Cost of revenue
-21,63 m
-
-
-
Research and development expenses
22,39 m
10,84 m
13,39 m
15,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,77 m
7,38 m
7,66 m
7,23 m
Operating expense
29,17 m
18,22 m
21,05 m
22,23 m
Total operating expenses
7,53 m
18,22 m
21,05 m
22,23 m
Operating income
-7,53 m
-18,22 m
-21,05 m
-22,23 m
Other non operating income
-
1,46 m
1,46 m
1,76 m
EBT including unusual items
-12,73 m
-16,38 m
-19,59 m
-20,47 m
EBT excluding unusual items
-6,49 m
-16,75 m
-19,59 m
-20,47 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,73 m
-16,38 m
-19,59 m
-20,47 m
Net profit margin
-
-
-
-
Earnings per share
-
-0,10
-0,11
-0,11
Interest and investment income
1,04 m
-
-
-
Interest expense
-
-
-
-
Net interest expenses
1,04 m
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-7,53 m
-18,20 m
-21,04 m
-22,21 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme